Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
AP-303 by Shanghai Alebund Pharmaceuticals for Diabetic Nephropathy: Likelihood of Approval
AP-303 is under clinical development by Shanghai Alebund Pharmaceuticals and currently in Phase I for Diabetic Nephropathy. According to GlobalData,...
AP-303 by Shanghai Alebund Pharmaceuticals for Diabetic Nephropathy: Likelihood of Approval
AP-303 is under clinical development by Shanghai Alebund Pharmaceuticals and currently in Phase I for Diabetic Nephropathy. According to GlobalData,...
AP-301 by Shanghai Alebund Pharmaceuticals for Hyperphosphatemia: Likelihood of Approval
AP-301 is under clinical development by Shanghai Alebund Pharmaceuticals and currently in Phase I for Hyperphosphatemia. According to GlobalData, Phase...